Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020
2020-08-29 · Ionis Pharmaceuticals · original ionis.com ↗
Results from Phase 2 study demonstrate patients receiving vupanorsen experienced significant, dose-dependent reductions in triglyceride levels, ANGPTL3 and additional lipid parameters compared to placebo Favorable safety and tolerability profile demonstrated for LICA platform-based therapy Results from the Phase 2 study to be published in the European Heart Journal BOSTON and CARLSBAD, Calif., Aug. 29, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), presented data from the Phase 2 clinical trial of vupanorsen (AKCEA-ANGPTL3-LRx) in an online Late Breaking Clinical Trial Session at the ESC Congress 2020, the annual meeting for the European Society of Cardiology.
The release as fetched from its publisher. ionis.com ↗